Henry Meds offers low-cost compounded tirzepatide ($297/month) with async-only intake. Runs a 503A pharmacy model. One of the lowest-priced legitimate compounded options. Trade-offs: async-only with no video consult; limited pharmacy disclosure beyond 503A.
| Pricing | $297/mo |
|---|---|
| Pharmacy | 503A only |
| Clinician | NP/PA |
| States | 50 states |
| Editorial score | 78 / 100 |
Henry Meds offers low-cost compounded tirzepatide ($297/month) with async-only intake. Runs a 503A pharmacy model. One of the lowest-priced legitimate compounded options. Trade-offs: async-only with no video consult; limited pharmacy disclosure beyond 503A. See the methodology for how this score was calculated.
NexLife (our #1 pick, 94/100) outscores Henry Meds on flat-rate pricing transparency, dual 503A/503B pharmacy disclosure, and MD/DO clinical oversight. Use the right-hand panel to compare directly.
Compounded semaglutide + tirzepatide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000